DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hill, G.
Right arrow Articles by Ward, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hill, G.
Right arrow Articles by Ward, P.

Vol. 30, Issue 1, 13-19, January 2002

The Anti-Influenza Drug Oseltamivir Exhibits Low Potential to Induce Pharmacokinetic Drug Interactions via Renal Secretion---Correlation of in Vivo and in Vitro Studies

George Hill, Tomas Cihlar, Charles Oo, Edmund S. Ho, Ken Prior, Hugh Wiltshire, Jo Barrett, Baulian Liu, and Penny Ward

Roche Pharmaceutical Global Development, Palo Alto, California (G.H.), Nutley, New Jersey (C.O., B.L.), and Welwyn, United Kingdom (J.B., P.W.); Gilead Sciences, Foster City, California (T.C., E.S.H.); and Roche Discovery, Welwyn, United Kingdom (K.P., H.W.)

Oseltamivir is an ester prodrug of the active metabolite [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a potent and selective inhibitor of neuraminidase enzyme of influenza virus. Oseltamivir is rapidly hydrolyzed by hepatic carboxylesterases to Ro 64-0802, which is then exclusively excreted by glomerular filtration and active tubular secretion without further metabolism. In vivo and in vitro studies were conducted to evaluate the renal drug-drug interaction potential of oseltamivir. Crossover studies were conducted in healthy subjects in which oral oseltamivir was administered alone and coadministered with probenecid, cimetidine, or amoxicillin. Probenecid completely blocked the renal secretion of Ro 64-0802, increasing systemic exposure (area under the curve) by 2.5-fold, but no interaction was observed with cimetidine or amoxicillin. These in vivo data show that Ro 64-0802 is secreted via an organic anion pathway, but Ro 64-0802 does not inhibit amoxicillin renal secretion. In vitro effects of Ro 64-0802 on the human renal organic anionic transporter 1 (hOAT1) were investigated using novel Chinese hamster ovary cells stably transfected with hOAT1. Ro 64-0802 was found to be a low-efficiency substrate for hOAT1 and a very weak inhibitor of hOAT1-mediated transport of p-aminohippuric acid (PAH). Ro 64-0802 did not inhibit the hOAT1-mediated transport of amoxicillin. In contrast, probenecid effectively inhibited the transport of PAH, Ro 64-0802, and amoxicillin via hOAT1. These in vitro observations are consistent with the in vivo data, validating the usefulness of the in vitro system for evaluating such drug-drug interaction. The study results demonstrate that oseltamivir has a low drug-drug interaction potential at the renal tubular level due to inhibition of hOAT1.

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
G. Hoffmann, C. Funk, S. Fowler, M. B. Otteneder, A. Breidenbach, C. R. Rayner, T. Chu, and E. P. Prinssen
Nonclinical Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in the Central Nervous System
Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4753 - 4761.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
Y. Wattanagoon, K. Stepniewska, N. Lindegardh, S. Pukrittayakamee, U. Silachamroon, W. Piyaphanee, T. Singtoroj, W. Hanpithakpong, G. Davies, J. Tarning, et al.
Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers
Antimicrob. Agents Chemother., March 1, 2009; 53(3): 945 - 952.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Ose, M. Ito, H. Kusuhara, K. Yamatsugu, M. Kanai, M. Shibasaki, M. Hosokawa, J. D. Schuetz, and Y. Sugiyama
Limited Brain Distribution of [3R,4R,5S]-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (Ro 64-0802), a Pharmacologically Active Form of Oseltamivir, by Active Efflux across the Blood-Brain Barrier Mediated by Organic Anion Transporter 3 (Oat3/Slc22a8) and Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4)
Drug Metab. Dispos., February 1, 2009; 37(2): 315 - 321.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. S. Jhee, M. Yen, L. Ereshefsky, M. Leibowitz, M. Schulte, B. Kaeser, L. Boak, A. Patel, G. Hoffmann, E. P. Prinssen, et al.
Low Penetration of Oseltamivir and Its Carboxylate into Cerebrospinal Fluid in Healthy Japanese and Caucasian Volunteers
Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3687 - 3693.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Holodniy, S. R. Penzak, T. M. Straight, R. T. Davey, K. K. Lee, M. B. Goetz, D. W. Raisch, F. Cunningham, E. T. Lin, N. Olivo, et al.
Pharmacokinetics and Tolerability of Oseltamivir Combined with Probenecid
Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3013 - 3021.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
C. R. Rayner, P. Chanu, R. Gieschke, L. M. Boak, and E. N. Jonsson
Population Pharmacokinetics of Oseltamivir When Coadministered With Probenecid
J. Clin. Pharmacol., August 1, 2008; 48(8): 935 - 947.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Ose, H. Kusuhara, K. Yamatsugu, M. Kanai, M. Shibasaki, T. Fujita, A. Yamamoto, and Y. Sugiyama
P-glycoprotein Restricts the Penetration of Oseltamivir Across the Blood-Brain Barrier
Drug Metab. Dispos., February 1, 2008; 36(2): 427 - 434.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. Morimoto, M. Nakakariya, Y. Shirasaka, C. Kakinuma, T. Fujita, I. Tamai, and T. Ogihara
Oseltamivir (Tamiflu) Efflux Transport at the Blood-Brain Barrier via P-Glycoprotein
Drug Metab. Dispos., January 1, 2008; 36(1): 6 - 9.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
J. J. Schentag, G. Hill, T. Chu, and C. R. Rayner
Similarity in Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Japanese and Caucasian Subjects
J. Clin. Pharmacol., June 1, 2007; 47(6): 689 - 696.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Shi, J. Yang, D. Yang, E. L. LeCluyse, C. Black, L. You, F. Akhlaghi, and B. Yan
Anti-Influenza Prodrug Oseltamivir Is Activated by Carboxylesterase Human Carboxylesterase 1, and the Activation Is Inhibited by Antiplatelet Agent Clopidogrel
J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1477 - 1484.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Li, G. D. Anderson, B. R. Phillips, W. Kong, D. D. Shen, and J. Wang
INTERACTIONS OF AMOXICILLIN AND CEFACLOR WITH HUMAN RENAL ORGANIC ANION AND PEPTIDE TRANSPORTERS
Drug Metab. Dispos., April 1, 2006; 34(4): 547 - 555.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. C. Howton
Probenecid with oseltamivir for human influenza A (H5N1) virus infection?
N. Engl. J. Med., February 23, 2006; 354(8): 879 - 880.
[Full Text] [PDF]

Home page
 ChestHome page
S. S. Y. Wong and K.-y. Yuen
Avian Influenza Virus Infections in Humans
Chest, January 1, 2006; 129(1): 156 - 168.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Tahara, H. Kusuhara, H. Endou, H. Koepsell, T. Imaoka, E. Fuse, and Y. Sugiyama
A Species Difference in the Transport Activities of H2 Receptor Antagonists by Rat and Human Renal Organic Anion and Cation Transporters
J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 337 - 345.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. Oo, J. Barrett, A. Dorr, B. Liu, and P. Ward
Lack of Pharmacokinetic Interaction between the Oral Anti-Influenza Prodrug Oseltamivir and Aspirin
Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1993 - 1995.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.